sibles = European communicable disease bulletin 22, https://doi.org/10.2807/
1560-7917.Es.2017.22.13.30494 (2017).
29. Song, L. et al. Efﬁcacious recombinant inﬂuenza vaccines produced by high yield
bacterial expression: a solution to global pandemic and seasonal needs. PLoS
ONE 3, e2257 (2008).
30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent
seasonal ﬂu vaccine comprising recombinant hemagglutinin-ﬂagellin fusion
proteins. Open Forum Infect. Dis. 3, ofw015 (2016).
31. Aguilar-Yanez, J. M. et al. An inﬂuenza A/H1N1/2009 hemagglutinin vaccine
produced in Escherichia coli. PLoS ONE 5, e11694 (2010).
32. Saczynska, V. Inﬂuenza virus hemagglutinin as a vaccine antigen produced in
bacteria. Acta Biochim Pol. 61, 561–572 (2014).
33. Davis, A. R. et al. Immune response to human inﬂuenza virus hemagglutinin
expressed in Escherichia coli. Gene 21, 273–284 (1983).
34. Rosales-Mendoza, S. et al. What does plant-based vaccine technology offer to the
ﬁght against COVID-19? Vaccines 8, 183 (2020).
35. Pillet, S. et al. A plant-derived quadrivalent virus like particle inﬂuenza vaccine
induces cross-reactive antibody and T cell response in healthy adults. Clin.
Immunol. 168, 72–87 (2016).
36. Pillet, S. et al. Immunogenicity and safety of a quadrivalent plant-derived virus
like particle inﬂuenza vaccine candidate-two randomized Phase II clinical trials in
18 to 49 and >/=50 years old adults. PLoS ONE 14, e0216533 (2019).
37. Ward, B. J. et al. Efﬁcacy, immunogenicity, and safety of a plant-derived, quad-
rivalent, virus-like particle inﬂuenza vaccine in adults (18-64 years) and older
adults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396,
1491–1503 (2020).
38. Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant-
derived virus-like particles bearing inﬂuenza hemagglutinin. Vaccine 36,
8028–8038 (2018).
39. Pandey, A. et al. Impact of preexisting adenovirus vector immunity on immu-
nogenicity and protection conferred with an adenovirus-based H5N1 inﬂuenza
vaccine. PLoS ONE 7, e33428–e33428 (2012).
40. Sayedahmed, E. E. et al. Adenoviral vector-based vaccine platforms for devel-
oping the next generation of inﬂuenza vaccines. Vaccines 8, 574 (2020).
41. Xiang, K. et al. Progress on adenovirus-vectored universal inﬂuenza vaccines.
Hum. Vaccin Immunother. 11, 1209–1222 (2015).
42. Chen, J. R. et al. Better inﬂuenza vaccines: an industry perspective. J. Biomed. Sci.
27, 33 (2020).
43. Report to the president on reengeneering the inﬂuenza vaccine production
enterprise to meet the challenges of pandemic inﬂuenza. Available at https://
obamawhitehouse.archives.gov/sites/default/ﬁles/microsites/ostp/PCAST-
Inﬂuenza-Vaccinology-Report.pdf. Accessed August 2021.
44. López-Macías, C. et al. Safety and immunogenicity of a virus-like particle pan-
demic inﬂuenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-
controlled trial of adults in Mexico. Vaccine 29, 7826–7834 (2011).